AxoGen (NASDAQ:AXGN) Sets New 1-Year High – Should You Buy?

AxoGen, Inc. (NASDAQ:AXGN) shares reached a new 52-week high on Thursday . The company traded as high as $19.03 and last traded at $18.89, with a volume of 457510 shares. The stock had previously closed at $18.97.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of AxoGen from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th.

AxoGen Price Performance

The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47. The stock has a market cap of $798.31 million, a P/E ratio of -56.69 and a beta of 1.01. The company’s 50 day simple moving average is $15.64 and its 200 day simple moving average is $13.41.

Institutional Investors Weigh In On AxoGen

Several large investors have recently bought and sold shares of the company. Calamos Advisors LLC bought a new stake in shares of AxoGen during the fourth quarter worth $523,000. R Squared Ltd bought a new stake in shares of AxoGen during the fourth quarter worth $30,000. SG Americas Securities LLC increased its position in shares of AxoGen by 34.4% during the fourth quarter. SG Americas Securities LLC now owns 21,763 shares of the medical equipment provider’s stock worth $359,000 after acquiring an additional 5,576 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of AxoGen by 2,912.3% during the third quarter. JPMorgan Chase & Co. now owns 549,000 shares of the medical equipment provider’s stock worth $7,697,000 after acquiring an additional 530,775 shares in the last quarter. Finally, Principal Financial Group Inc. bought a new stake in shares of AxoGen during the third quarter worth $207,000. Institutional investors own 80.29% of the company’s stock.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.